Se Kon Won, MD
Cardiovascular Disease · Honolulu, HINPI 1881633865
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 60.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $3,881 and has fallen 52.8% since, to $1,832 in 2025.
Across 157 payments — averaging $71.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Boston Scientific$842
- Abiomed$740
- Novo Nordisk$461
- Boehringer Ingelheim$336
- Teleflex LLC$294
- plus $2K from 17 others
What the payments were for
- Consulting fees$1181%
- Travel & lodging$4,35839%
- Food & beverage$6,65359%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 48 | $6,752 |
| Boston Scientific | 6 | $842 |
| Abiomed | 18 | $740 |
| Novo Nordisk | 10 | $461 |
| Boehringer Ingelheim | 16 | $336 |
| Teleflex LLC | 3 | $294 |
| Bridgebio Pharma, Inc. | 5 | $264 |
| Shockwave Medical, Inc | 6 | $245 |
| Lantheus Medical Imaging, Inc. | 10 | $222 |
| AstraZeneca | 2 | $171 |
| Alnylam Pharmaceuticals Inc. | 10 | $168 |
| Acist Medical Systems, Inc. | 3 | $150 |
| Merck | 1 | $125 |
| Bayer | 5 | $121 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| Medtronic | 3 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $56 |
| Cardiovascular Systems Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Amgen | 1 | $22 |
| Biosense Webster, Inc. | 1 | $19 |
| Penumbra, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnilink Elite vascular stent system$1,964
- OMNILINK ELITE$1,605
- Xience V coronary stent system$1,077
- Watchman$581
- Agilis HisPro$154
- XIENCE SIERRA$148
- GUIDELINER$128
- VERQUVO$125
- Ozempic$125
- AVEIR$122
- WAINUA$121
- SUPERCROSS$117
How this compares
$11,215 in reported general payments places this provider in the 85th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 368 | $392,082 |
| OzempicSemaglutide | 117 | $139,208 |
| XareltoRivaroxaban | 83 | $110,491 |
| EntrestoSacubitril/Valsartan | 117 | $109,218 |
| FarxigaDapagliflozin Propanediol | 116 | $90,038 |
| JardianceEmpagliflozin | 78 | $78,016 |
| MounjaroTirzepatide | 50 | $74,805 |
| WegovySemaglutide | 30 | $39,411 |
| Repatha SureclickEvolocumab | 45 | $32,829 |
| Praluent PenAlirocumab | 46 | $31,955 |
| TrulicityDulaglutide | 15 | $17,957 |
| BrilintaTicagrelor | 25 | $17,883 |
| Atorvastatin Calcium | 298 | $7,264 |
| Metoprolol Succinate | 531 | $6,645 |
| Carvedilol ErCarvedilol Phosphate | 13 | $5,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $461 | $178,619147 claims |
| AstraZenecaFarxiga, Brilinta | $171 | $107,920141 claims |
| Boehringer IngelheimJardiance | $336 | $78,01678 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Honolulu
- Dipanjan BanerjeeHonolulu$331K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- William DangHonolulu$16K
- Edward ShenHonolulu$12K
- Wesley KaiHonolulu$10K
- Calvin WongHonolulu$8K
- Abdulelah NuqaliHonolulu$7K
- Mahdi Veillet-ChowdhuryHonolulu$7K
- Nath LimpruttidhamHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.